Nintedinib has been studied in 39 children (6â17 yrs) with fibrosing ILD demonstrating pharmacokinetics (wt based dosi
Tweet Content
Nintedinib has been studied in 39 children (6–17 yrs) with fibrosing ILD demonstrating pharmacokinetics (wt based dosing) and safety. Adjusted mean changes in FVC % at week 24 were 0.3 with nintedanib and −0.9 with placebo https://t.co/yQ7OREzpTR https://t.co/iylG9BZiz4
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off